Appointment of Internal Auditor of the Company.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of Orchid Pharma Limited, a Dhanuka Group company, convened on May 25, 2026 and approved the audited standalone and consolidated financial results for Q4 and financial year ended March 31, 2026. Standalone revenue stood at Rs 81,133 lakhs (vs Rs 92,193 lakh in FY25) and standalone profit before tax was Rs 4,521 lakh (vs Rs 10,648 lakh in FY25), reflecting a significant decline in profitability. The statutory auditor, M/s Singhi & Co., issued an unmodified opinion on standalone results but a qualified opinion on consolidated results due to unaudited US subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.) whose financials were provided by management. The Board also appointed an Internal Auditor for FY 2026-27. Additionally, the company disclosed progress on a proposed amalgamation of holding company Dhanuka Laboratories Limited with Orchid Pharma (NCLT order awaited), and the full acquisition of Enmetazobactam (EXBLIFEP) from Allecra Therapeutics in Germany and France.
The appointment of an internal auditor is a routine compliance matter with no immediate shareholder impact. The qualified opinion on consolidated results due to unaudited US subsidiaries is a recurring governance concern worth monitoring, particularly as the company expands its international footprint through recent acquisitions in Europe and the US.